REHOVOT, Israel, March 14, 2019 /PRNewswire/ -- Tikcro Technologies Ltd. TIKRF, a pre-clinical stage antibody immunotherapy company leveraging a novel mimitope approach for antibody generation, today announced that it will present a scientific poster featuring the unique properties of a novel CTLA-4 antibody at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held at the Georgia World Congress Center in Atlanta, GA on Friday, March 29, 2019 – Wednesday, April 3, 2019.
The poster titled "A CTLA4 antibody with enhanced properties" will feature TikAb, a full human CTLA-4 antibody, and in-vitro and in-vivo assay results with comparative data to the existing treatment will be presented.
Title: A CTLA-4 antibody with enhanced properties
Date: Tuesday, April 2, 2019
Time: 8:00am – 12:00pm ET
Session: Immune Checkpoints 1
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24
Additional abstract information is available here: https://www.abstractsonline.com/pp8/#!/6812/presentation/2667
About Tikcro Technologies
Tikcro Technologies Ltd. TIKRF supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com.
View original content:http://www.prnewswire.com/news-releases/tikcro-technologies-to-present-unique-properties-of-a-novel-ctla-4-antibody-at-the-aacr-annual-meeting-2019-in-the-us-300812028.html
SOURCE Tikcro Technologies Ltd.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.